BrainStorm Cell Therapeutics Inc. (BCLI) bonds
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
BrainStorm Cell Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in BrainStorm Cell Therapeutics's 10-Q for the period ended Jun 15, 2026
| Issue | Coupon | Amount issued |
|---|---|---|
| Convertible promissory note, November 10, 2025 Convertible | – | $143.75M |
| Convertible promissory note, November 20, 2025 Convertible | – | $180.00M |
| Convertible promissory note, October 31, 2025 Convertible | 12.00% | $182.40M |
| Loan agreement | 8.50% | $15.00M |
| Unsecured Convertible Promissory Note, May 11, 2026 Convertible | 12.00% | $151.80M |
| Unsecured Convertible Promissory Note, May 5 , 2026 Convertible | 12.00% | $151.80M |
| Unsecured promissory note Convertible | 12.00% | $140.00M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?